Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Assets (2019 - 2026)

Outset Medical has reported Assets over the past 7 years, most recently at $264.5 million for Q4 2025.

  • Quarterly Assets fell 4.1% to $264.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $264.5 million through Dec 2025, down 4.1% year-over-year, with the annual reading at $264.5 million for FY2025, 4.1% down from the prior year.
  • Assets was $264.5 million for Q4 2025 at Outset Medical, down from $277.3 million in the prior quarter.
  • Over five years, Assets peaked at $504.8 million in Q2 2021 and troughed at $264.5 million in Q4 2025.
  • The 5-year median for Assets is $340.3 million (2023), against an average of $355.8 million.
  • Year-over-year, Assets grew 14.77% in 2021 and then fell 25.18% in 2022.
  • A 5-year view of Assets shows it stood at $463.5 million in 2021, then fell by 13.67% to $400.1 million in 2022, then decreased by 21.57% to $313.8 million in 2023, then decreased by 12.11% to $275.8 million in 2024, then decreased by 4.1% to $264.5 million in 2025.
  • Per Business Quant, the three most recent readings for OM's Assets are $264.5 million (Q4 2025), $277.3 million (Q3 2025), and $288.8 million (Q2 2025).